{"id":1110,"date":"2020-09-03T18:08:00","date_gmt":"2020-09-03T16:08:00","guid":{"rendered":"https:\/\/euroconsum.eu\/?p=1110"},"modified":"2023-04-09T08:03:10","modified_gmt":"2023-04-09T06:03:10","slug":"archiv-alternative-krebstherapien-immer-ein-risiko","status":"publish","type":"post","link":"https:\/\/euroconsum.eu\/cs\/2020\/09\/03\/archiv-alternative-krebstherapien-immer-ein-risiko\/","title":{"rendered":"Alternativn\u00ed l\u00e9\u010dba rakoviny - v\u017edy je to riziko"},"content":{"rendered":"<figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"720\" height=\"480\" src=\"https:\/\/euroconsum.eu\/wp-content\/uploads\/2022\/03\/Bild_2022-03-11_235720.png\" alt=\"\" class=\"wp-image-1648\"\/><figcaption>Obr\u00e1zek: marijana1\/Pixabay (licence CCO)<\/figcaption><\/figure>\n\n\n\n<p>Diagn\u00f3za rakoviny je v\u017edy ud\u00e1lost\u00ed, kter\u00e1 zm\u011bn\u00ed v\u00e1\u0161 \u017eivot. Krom\u011b v\u0161eho ostatn\u00edho vyvol\u00e1v\u00e1 tak\u00e9 mnoho pochybnost\u00ed a nejistoty ohledn\u011b mo\u017enost\u00ed l\u00e9\u010dby. Lid\u00e9 se ne v\u017edy \u0159\u00edd\u00ed radami onkologick\u00fdch odborn\u00edk\u016f, ale uchyluj\u00ed se k tzv. alternativn\u00ed medic\u00edn\u011b.<\/p>\n\n\n\n<!--more-->\n\n\n\n<p>Odborn\u00edci p\u0159ed t\u00edm v\u017edy varovali. Nyn\u00ed jsou k dispozici tak\u00e9 dob\u0159e podlo\u017een\u00e9 v\u00fdsledky v ot\u00e1zce, jak jsou na tom pacienti, kte\u0159\u00ed byli l\u00e9\u010deni pouze podle v\u011bdeck\u00fdch metod, ve srovn\u00e1n\u00ed s t\u011bmi, kte\u0159\u00ed se spol\u00e9hali v\u00fdhradn\u011b na \"alternativn\u00ed medic\u00ednu\". V roce 2017 publikovali v\u011bdci z Yaleovy univerzity v USA vysoce cen\u011bnou studii na toto t\u00e9ma.<sup><a href=\"https:\/\/euroconsum.eu\/cs\/publication\/alternative-krebstherapien-immer-risiko\/#fn:1\">1<\/a><\/sup>&nbsp;provedeno.<\/p>\n\n\n\n<p>Na z\u00e1klad\u011b americk\u00e9ho onkologick\u00e9ho registru byly sestaveny dv\u011b srovn\u00e1vac\u00ed skupiny konven\u010dn\u011b a v\u011bdecky l\u00e9\u010den\u00fdch pacient\u016f. Pacienti m\u011bli nej\u010dast\u011bj\u0161\u00ed typy rakoviny (rakovinu prsu, prostaty, plic nebo tlust\u00e9ho st\u0159eva), ale je\u0161t\u011b nem\u011bli metast\u00e1zy. M\u00edra p\u0159e\u017eit\u00ed obou skupin byla porovn\u00e1v\u00e1na po dobu sedmi let.<\/p>\n\n\n\n<p>V\u00fdsledek je jasn\u00fd: v ka\u017ed\u00e9m \u010dasov\u00e9m okam\u017eiku je po\u010det \u00famrt\u00ed p\u0159i alternativn\u00ed l\u00e9\u010db\u011b p\u0159ibli\u017en\u011b dvakr\u00e1t vy\u0161\u0161\u00ed ne\u017e u konven\u010dn\u011b l\u00e9\u010den\u00fdch osob. Po sedmi letech zem\u0159ela p\u0159i alternativn\u00ed l\u00e9\u010db\u011b p\u0159ibli\u017en\u011b polovina pacient\u016f a p\u0159i konven\u010dn\u00ed l\u00e9\u010db\u011b jen dobr\u00e1 \u010dtvrtina. V z\u00e1vislosti na typu rakoviny byl rozd\u00edl je\u0161t\u011b v\u00fdrazn\u011bj\u0161\u00ed. A tento trend bude skute\u010dn\u011b pokra\u010dovat - z \u010dist\u011b statistick\u00e9ho hlediska a\u017e do bodu, kdy v\u0161ichni alternativn\u011b l\u00e9\u010den\u00ed pacienti zem\u0159eli a p\u0159ibli\u017en\u011b polovina v\u011bdecky l\u00e9\u010den\u00fdch st\u00e1le \u017eije.<\/p>\n\n\n\n<p>Jedn\u00e1 se p\u0159edev\u0161\u00edm o \u00favahu, kter\u00e1 jasn\u011b odd\u011bluje \"pouze v\u011bdeckou\" a \"pouze alternativn\u00ed\" l\u00e9\u010dbu. Je ov\u0161em zaj\u00edmav\u00e9 zjistit, zda takov\u00e9 \u00fa\u010dinky m\u00e1 i \"komplement\u00e1rn\u00ed\" l\u00e9\u010dba, tj. takov\u00e1, kter\u00e1 kombinuje v\u011bdeck\u00e9 a alternativn\u00ed l\u00e9\u010debn\u00e9 p\u0159\u00edstupy.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-css-opacity\"\/>\n\n\n\n<p>Yale\u016fv t\u00fdm na to nav\u00e1zal v&nbsp;<strong>N\u00e1sledn\u00e1 studie<\/strong><sup><a href=\"https:\/\/euroconsum.eu\/cs\/publication\/alternative-krebstherapien-immer-risiko\/#fn:2\">2<\/a><\/sup>&nbsp;Uk\u00e1zalo se, \u017ee i v t\u00e9to konstelaci se u pacient\u016f, kte\u0159\u00ed dost\u00e1vali dopl\u0148kovou l\u00e9\u010dbu, jasn\u011b projevily nev\u00fdhody. V\u00fdzkumn\u00edci to p\u0159i\u010d\u00edtaj\u00ed tomu, \u017ee v t\u00e9to skupin\u011b nebyly p\u0159i konven\u010dn\u00ed l\u00e9\u010db\u011b neobvykl\u00e9 prodlevy a odm\u00edt\u00e1n\u00ed terapie. To ukazuje na tendenci pacient\u016f, kte\u0159\u00ed \"pouze\" podstupuj\u00ed l\u00e9\u010dbu komplement\u00e1rn\u00ed alternativn\u00ed medic\u00ednou, m\u00edt ni\u017e\u0161\u00ed compliance (tj. ochotu \u0159\u00eddit se doporu\u010den\u00edmi l\u00e9ka\u0159e). L\u00e9ka\u0159 si zde st\u011b\u017euje na \"ne\u00fapln\u00e9 dodr\u017eov\u00e1n\u00ed l\u00e9\u010dby\".<\/p>\n\n\n\n<p>Rozhodnut\u00ed ve prosp\u011bch alternativn\u00ed medic\u00edny v p\u0159\u00edpad\u011b sou\u010dasn\u00e9 diagn\u00f3zy rakoviny, kter\u00e1 je podle v\u011bdeck\u00e9ho hodnocen\u00ed pova\u017eov\u00e1na za vyl\u00e9\u010ditelnou, by se tedy mohlo uk\u00e1zat jako velk\u00e1 chyba - a to v ka\u017ed\u00e9 konstelaci, a\u0165 u\u017e se l\u00e9\u010d\u00ed v\u00fdhradn\u011b nebo dopl\u0148kov\u011b alternativn\u00ed medic\u00ednou. Auto\u0159i studie doporu\u010duj\u00ed, aby ka\u017ed\u00fd onkologick\u00fd l\u00e9ka\u0159 sv\u00e9 pacienty o t\u011bchto zji\u0161t\u011bn\u00edch jasn\u011b informoval.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-css-opacity\"\/>\n\n\n\n<ol class=\"wp-block-list\"><li>Johnson SB, Park HS, Gross CP, Yu JB: Use on Alternative Medicine for Cancer and its Impact on Survival; JNCI J Natl Cancer Inst (2018) 110(1): djx145, doi: 10.1093\/jnci\/djx145&nbsp;<a href=\"https:\/\/euroconsum.eu\/cs\/publication\/alternative-krebstherapien-immer-risiko\/#fnref:1\">\u21a9\ufe0e<\/a><\/li><li>Skyler B. Johnson, MD; Henry S. Park, MD, MPH; Cary P. Gross, MD; et al; Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers; JAMA Oncol. Zve\u0159ejn\u011bno online 19. \u010dervence 2018. doi:10.1001\/jamaoncol.2018.2487&nbsp;<a href=\"https:\/\/euroconsum.eu\/cs\/publication\/alternative-krebstherapien-immer-risiko\/#fnref:2\">\u21a9\ufe0e<\/a><\/li><\/ol>\n\n\n\n<hr class=\"wp-block-separator has-css-opacity\"\/>\n\n\n\n<h5 class=\"has-text-align-center wp-block-heading\">N\u011bmeck\u00e9 sdru\u017een\u00ed spot\u0159ebitel\u016f<\/h5>\n\n\n\n<h6 class=\"has-text-align-center wp-block-heading\">Na stran\u011b d\u016fkaz\u016f, na stran\u011b spot\u0159ebitel\u016f: N\u011bmeck\u00fd svaz spot\u0159ebitel\u016f je uzn\u00e1van\u00fdm neziskov\u00fdm sdru\u017een\u00edm na ochranu spot\u0159ebitel\u016f.<\/h6>","protected":false},"excerpt":{"rendered":"<p>Diagn\u00f3za rakoviny je v\u017edy ud\u00e1lost\u00ed, kter\u00e1 zm\u011bn\u00ed v\u00e1\u0161 \u017eivot. Krom\u011b v\u0161eho ostatn\u00edho vyvol\u00e1v\u00e1 tak\u00e9 mnoho pochybnost\u00ed a nejistoty ohledn\u011b mo\u017enost\u00ed l\u00e9\u010dby. Lid\u00e9 se ne v\u017edy \u0159\u00edd\u00ed radami onkologick\u00fdch odborn\u00edk\u016f, ale uchyluj\u00ed se k tzv. alternativn\u00ed medic\u00edn\u011b.<\/p>","protected":false},"author":1,"featured_media":1648,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[43],"class_list":["post-1110","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-heil-und-arzneimittel-therapien","tag-pseudomedizin"],"_links":{"self":[{"href":"https:\/\/euroconsum.eu\/cs\/wp-json\/wp\/v2\/posts\/1110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/euroconsum.eu\/cs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/euroconsum.eu\/cs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/euroconsum.eu\/cs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/euroconsum.eu\/cs\/wp-json\/wp\/v2\/comments?post=1110"}],"version-history":[{"count":9,"href":"https:\/\/euroconsum.eu\/cs\/wp-json\/wp\/v2\/posts\/1110\/revisions"}],"predecessor-version":[{"id":3553,"href":"https:\/\/euroconsum.eu\/cs\/wp-json\/wp\/v2\/posts\/1110\/revisions\/3553"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/euroconsum.eu\/cs\/wp-json\/wp\/v2\/media\/1648"}],"wp:attachment":[{"href":"https:\/\/euroconsum.eu\/cs\/wp-json\/wp\/v2\/media?parent=1110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/euroconsum.eu\/cs\/wp-json\/wp\/v2\/categories?post=1110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/euroconsum.eu\/cs\/wp-json\/wp\/v2\/tags?post=1110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}